# bluebird bio Inc. (BLUE)

Source: https://www.quantisnow.com/company/BLUE
Generated: 2026-11-17T04:02:07.106Z

- Ticker: BLUE
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2013
- Website: bluebirdbio.com

## About

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent Ã-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. bluebird bio, Inc. has a strategic alliance with National Resilience, Inc. to research, development, and delivery of cell therapies. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

## Latest BLUE news and filings

- 2025-06-12 10:05 UTC [SEC Form 15-12G filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-bluebird-bio-inc-6082974)
- 2025-06-04 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-bluebird-bio-inc-6071375)
- 2025-06-03 22:02 UTC [SEC Form 4] [Chief Business & Legal Officer Vittiglio Joseph returned 5,625 shares to the company and was granted 2,500 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-business-legal-officer-vittiglio-joseph-returned-5625-shares-to-6070975)
- 2025-06-03 21:46 UTC [SEC Form 4] [Director Agwunobi John O returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-agwunobi-john-o-returned-1245-shares-to-the-company-6070938)
- 2025-06-03 21:38 UTC [SEC Form 4] [Director Vachon Mark returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-vachon-mark-returned-1245-shares-to-the-company-closing-6070921)
- 2025-06-03 21:36 UTC [SEC Form 4] [Chief Medical Officer Colvin Richard A returned 6,666 shares to the company and was granted 2,500 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-colvin-richard-a-returned-6666-shares-to-6070912)
- 2025-06-03 21:35 UTC [SEC Form 4] [Director Tita-Reid Najoh returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-tita-reid-najoh-returned-1245-shares-to-the-company-closing-6070911)
- 2025-06-03 21:30 UTC [SEC Form 4] [President and CEO Obenshain Andrew returned 24,120 shares to the company and was granted 14,820 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-obenshain-andrew-returned-24120-shares-to-the-6070883)
- 2025-06-03 21:29 UTC [SEC Form 4] [Director Leiderman Elisabeth returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-leiderman-elisabeth-returned-1245-shares-to-the-company-closing-6070872)
- 2025-06-03 21:24 UTC [SEC Form 4] [Director Jones-Burton Charlotte returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-jones-burton-charlotte-returned-1245-shares-to-the-company-closing-6070822)
- 2025-06-03 21:21 UTC [SEC Form 4] [Officer Klima Thomas J returned 6,964 shares to the company and was granted 2,500 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/officer-klima-thomas-j-returned-6964-shares-to-the-company-6070797)
- 2025-06-03 21:21 UTC [SEC Form 4] [Chief Financial Officer Sterling O. James returned 7,500 shares to the company and was granted 2,500 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-sterling-o-james-returned-7500-shares-to-6070792)
- 2025-06-03 21:18 UTC [SEC Form 4] [Director Leschly Nick returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-leschly-nick-returned-1245-shares-to-the-company-closing-6070761)
- 2025-06-03 21:14 UTC [SEC Form 4] [Director Paulson Richard A. returned 1,323 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-paulson-richard-a-returned-1323-shares-to-the-company-6070715)
- 2025-06-03 21:11 UTC [SEC Form 4] [Director Cloonan Michael returned 1,867 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-cloonan-michael-returned-1867-shares-to-the-company-closing-6070701)
- 2025-06-02 14:37 UTC [SEC Form POS AM filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-bluebird-bio-inc-6066988)
- 2025-06-02 14:34 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-bluebird-bio-inc-6066984)
- 2025-06-02 14:33 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-bluebird-bio-inc-6066982)
- 2025-06-02 14:32 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-bluebird-bio-inc-6066980)
- 2025-06-02 14:32 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-bluebird-bio-inc-6066978)
- 2025-06-02 14:31 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-bluebird-bio-inc-6066976)
- 2025-06-02 14:30 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-bluebird-bio-inc-6066975)
- 2025-06-02 14:29 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-bluebird-bio-inc-6066969)
- 2025-06-02 14:28 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-bluebird-bio-inc-6066967)
- 2025-06-02 14:27 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-bluebird-bio-inc-6066966)
- 2025-06-02 14:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-bluebird-bio-inc-6066964)
- 2025-06-02 14:25 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-bluebird-bio-inc-6066963)
- 2025-06-02 14:25 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-bluebird-bio-inc-6066956)
- 2025-06-02 14:24 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-bluebird-bio-inc-6066952)
- 2025-06-02 14:23 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-bluebird-bio-inc-6066950)
- 2025-06-02 12:43 UTC [SEC Form 8-K] [bluebird bio Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update](https://www.quantisnow.com/insight/bluebird-bio-inc-filed-sec-form-8-k-completion-of-acquisition-6066720)
- 2025-06-02 12:34 UTC [bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital](https://www.quantisnow.com/insight/bluebird-bio-announces-completion-of-acquisition-by-carlyle-and-sk-6066676)
- 2025-05-30 12:55 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by bluebird bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-bluebird-bio-inc-6064467)
- 2025-05-30 12:30 UTC [Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer](https://www.quantisnow.com/insight/carlyle-and-sk-capital-partners-announce-expiration-of-bluebird-bio-6064401)
- 2025-05-27 20:16 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by bluebird bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-bluebird-bio-inc-6059116)
- 2025-05-27 12:30 UTC [bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital](https://www.quantisnow.com/insight/bluebird-bio-reminds-stockholders-to-act-now-to-tender-shares-6058276)
- 2025-05-20 20:38 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by bluebird bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-bluebird-bio-inc-6050590)
- 2025-05-16 20:43 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by bluebird bio Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-bluebird-bio-inc-6045776)
- 2025-05-16 20:30 UTC [Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions](https://www.quantisnow.com/insight/carlyle-sk-capital-partners-and-bluebird-bio-provide-updated-tender-6045556)
- 2025-05-14 21:14 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by bluebird bio Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bluebird-bio-inc-6039892)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/BLUE
- Earnings history: https://www.quantisnow.com/earnings/BLUE
- Dividend history: https://www.quantisnow.com/dividends/BLUE
- Insider transactions: https://www.quantisnow.com/insiders/BLUE
- Options chain: https://www.quantisnow.com/options/BLUE
- SEC 8-K filings only: https://www.quantisnow.com/company/BLUE/8-k
- RSS and alerts for BLUE: https://www.quantisnow.com/docs/rss-feeds.md
